The National Medical Products Administration has approved the listing of succinic acid amylum nicotinamide tablets.

Recently, the National Medical Products Administration approved the application of Changchun Jilin Ma Pharmaceutical Group Co., Ltd. for the listing of a first-class innovative drug, Amber Anwu Yaping Tablets. This drug is a cholinesterase inhibitor used to treat mild to moderate symptoms of Alzheimer's disease. The listing of this drug provides patients with a new treatment option.